Harvard’s “Chemical Cocktail” That Reverses Cell Age
What the Paper Actually Shows (and What It Doesn’t)
In July 2023 a Harvard Medical School team led by David Sinclair published a paper claiming that six chemical cocktails could reset aging human cells to a younger state in under a week. The cells kept their identity. Gene therapy was no longer required. Headlines followed. So did the usual questions: Can I just take this? Is there a supplement? Do I need an IV?
The short answer is no, no, and no. Here’s the longer one.
What the study actually did
The paper, “Chemically induced reprogramming to reverse cellular aging,” appeared in the journal *Aging*. Researchers screened small-molecule combinations using high-throughput assays, including transcriptomic aging clocks and a nucleocytoplasmic compartmentalization (NCC) test that distinguishes young, old, and senescent cells.
They identified six cocktails. In cultured human fibroblasts (including senescent ones), the mixes restored more youthful gene-expression profiles, lowered transcriptomic age, and improved NCC within about four days. The strongest basal recipe was:
- VC6TF: valproic acid,
- CHIR-99021,
- E-616452 (also called RepSox),
- tranylcypromine,
- and forskolin.
Related cocktails added boosters such as sodium butyrate or growth factors. A parallel series used different base molecules. Critically, the cells did not lose their identity and turn into pluripotent stem cells.
Get chuckfresh’s stories in your inbox
Join Medium for free to get updates from this writer.
This was framed as a chemical alternative to earlier OSK gene-therapy work from the same lab (the three Yamanaka factors that had shown some functional benefits in mice). The paper itself is measured. The surrounding commentary was not.
The gap between cells in a dish and a living body
No animals were treated with these exact published cocktails and then shown to live longer or function better. No humans were treated at all. Transcriptomic clocks and compartmentalization markers are useful, but they are not the same as restored tissue function, reduced disease, or extended healthy lifespan.
Experts outside the lab noted the distinction. Biogerontologist Matt Kaeberlein publicly stated that claims of a chemical approach that reverses aging overstated the data: nobody has a drug that reverses aging.
Charles Brenner and others highlighted both the preliminary nature of the findings and the fact that several of the molecules have known toxicity profiles. Valproic acid carries a black-box warning. Tranylcypromine is a monoamine oxidase inhibitor with dietary and drug-interaction restrictions. Concentrations that work in culture media are often harsh.
Later work by other groups (including a 2025 *EMBO Molecular Medicine* paper from Alejandro Ocampo’s lab) simplified related chemical ideas to just two molecules (RepSox + tranylcypromine). Those improved certain aging hallmarks in aged human cells and extended median lifespan in *C. elegans* worms by roughly 42% at a low dose. Worm data are useful for screening; they are not mammalian proof.
Sinclair has described ongoing unpublished animal studies on improved oral agents (sometimes referred to under codes like SL-100) and has discussed plans for human testing in the context of the XPrize Healthspan competition. As of late 2026 those remain experimental. Separate gene-therapy efforts (Life Biosciences’ ER-100) have entered early human trials for optic-nerve conditions, but that is a different technology: viral delivery of OSK genes into the eye, not a systemic chemical pill.
Supplements, prescriptions, and the DIY problem: It’s not for sale anywhere, and you should NOT try this yourself!
One component, forskolin (from the plant *Coleus forskohlii*), is sold as a dietary supplement, typically studied at 250–500 mg/day of a 10% extract for other purposes. It is not the cocktail. The rest of the mix consists of prescription drugs or research chemicals that are not available or safe as over-the-counter supplements.
There is no commercial product that delivers the published cocktails at the concentrations used in the cell studies. Attempting to assemble them yourself would require obtaining controlled substances or research reagents, guessing at systemic doses that have never been established for this purpose, and accepting unknown risks of toxicity, organ damage, and drug interactions. Cell-culture conditions do not translate directly to oral or intravenous delivery in a human.
IV administration is not a shortcut. The original experiments simply added the compounds to the media surrounding the cells. Getting the right amounts into the right cells throughout a living body, without unacceptable toxicity, is an unsolved delivery and safety problem. Sinclair’s public comments have emphasized oral mixtures for whole-body effects, not IVs.
The bottom line
The 2023 paper is real, peer-reviewed work showing that certain chemical combinations can shift molecular aging markers in cultured human cells toward a younger state while preserving identity. It is an incremental step in the partial-reprogramming literature, not a proven anti-aging therapy.
No human can currently “do this themselves” with any reasonable expectation of benefit and safety. No matching supplements exist. Neither oral nor IV versions are available or recommended outside of controlled research settings that have not yet produced public positive human results for these chemicals.
If the field advances, it will do so through proper animal toxicology, dose-finding, and human trials — not through kitchen-table cocktails. Until then, the distance between a rejuvenated fibroblast in a dish and a rejuvenated human remains large.
